Protein Kinase Inhibitors

Kinase Inhibitor

Leukemia, Myeloid

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Ponatinib is a kinase inhibitor. The chemical name for ponatinib hydrochloride is 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide hydrochloride. The molecular formula is C<span class="Sub">29</span>H<span class="Sub">28</span>ClF<span class="Sub">3</span>N<span class="Sub">6</span>O which corresponds to a formula weight of 569.02 g/mol. Its structure is shown below:</p><div class="Figure"><img alt="Chemical Structure" src="iclusig-01.jpg"/></div><p>Ponatinib HCl is an off-white to yellow powder with pKa of 2.77 and 7.8. The solubility of ponatinib in pH 1.7, 2.7, and 7.5 buffers is 7790 mcg/mL, 3.44 mcg/mL, and 0.16 mcg/mL, respectively, indicating a decrease in solubility with increasing pH. Each tablet for oral administration contains 10 mg, 15 mg, 30 mg or 45 mg of ponatinib equivalent to 10.68 mg, 16.03 mg, 32.05 mg, and 48.08 mg of ponatinib hydrochloride with the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (type B), colloidal silicon dioxide, magnesium stearate and a tablet coating. The tablet coating consists of talc, polyethylene glycol, polyvinyl alcohol, and titanium dioxide.</p></section>

Iclusig

ponatinib

ponatinib 15 MG Oral Tablet

ponatinib 15 MG Oral Tablet [Iclusig]

ponatinib 45 MG Oral Tablet

ponatinib 45 MG Oral Tablet [Iclusig]

ponatinib 30 MG Oral Tablet

ponatinib 30 MG Oral Tablet [Iclusig]

ponatinib 10 MG Oral Tablet

ponatinib 10 MG Oral Tablet [Iclusig]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Medication Guide 

Pharmacy List 

How To Order Iclusig

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity 

Takeda Oncology Here2Assist Enrollment Form 

Takeda Oncology Here2Assist Enrollment Form - Spanish

Enroll in Patient Savings Program 

Takeda Oncology Patient Assistance Program

Takeda Oncology Patient Assistance Program - Spanish

Patient Profiles: CML 

About Iclusig: CML 

Taking Iclusig: CML

Side Effects: CML

Patient Resources: CML

Patient Brochure: CML

Iclusig Dcotor Discussion Guide 

Patient Brochure: Ph+ ALL 

About Iclusig: Ph+ ALL 

Taking Iclusig: Ph+ ALL 

Side Effects: Ph+ ALL

Patient Resources: Ph+ ALL 

Instructions For Use: CML

Instructions For Use: Ph+ ALL

Submit MSL Request 